Sanjeev Valentine’s Post

🚀 The PitchBook Q1 2024 Medtech Report is Here! 🚀 📈 Key Highlights: > Emerging innovations in whole-body scans & cardiac arrest devices > Company spotlights on Healthy.IO (at-home diagnostics) & Paige (AI imaging diagnostics) > Detailed company & deal analysis in the workspace and ACV + market map 💡 Takeaways: 1. Medtech deal activity rebounded to $3.3B in Q1 from $2.8B in Q4 Potential interest rate cuts may stabilize VC funding 2. FTC's decision on Boston-Axonics deal could impact future medtech acquisitions 3. Cardiovascular M&A is thriving: Potential targets include Cardiac Dimensions, R3 Vascular, and Corvia Medical 4. Opportunity for expansion in general diagnostic MRI screening Innovations in predicting out-of-hospital cardiac events could improve survival rates #Medtech #Innovation #VCFunding #Healthcare #M&A #Diagnostics #Cardiovascular #MRI #CardiacArrest

Looking at the future of cardiac care, how can major device companies collaborate with the startup ecosystem? In this clip Chris Eso, Vice President, Global Head of Corporate and Business Development, M&A and Ventures at Medtronic, predicts that in the next 10-20 years, medical devices will be highly interconnected and data-driven. This shift marks a significant shift from traditional Medtech. Achieving this level of connectivity will require extensive collaboration between major device companies and the startup ecosystem. The full panel shares insights on fostering successful partnerships, enhancing patient care, and driving the next wave of breakthroughs in cardiac treatment and management. Tune into the full panel “Accelerating Cardiac Care Innovation: How Can Major Device Companies Collaborate with the Startup Ecosystem?” to hear more from Ken Nelson, Nate Harrington, Lisa Suennen, GCB.D, Chris Eso, and David Hochman.

More to come

I love seeing these clips from LSI USA 2024. That conference went by so quickly that I missed too many terrific panels! I appreciate Chris Eso's take in this clip: “If you think about what the world looks like in 10-15-20 years from now from a medical device, it’s going to be all connected. It’s going to be all data generating. It’s going to be how you use that data to get better outcomes longer term.” This is exactly why The Shape Sensing Company is building tools to track surgical devices. Not just for navigation during procedures (which is a huge benefit), but the data associated with the navigation will inform us on what went right, what went wrong, and how to improve patient outcomes in the future. Fiber optic 3D guidance is the only technology that can provide full-length, three-dimensional device location, bending, and torque tracking for any tool used in a procedure. And we're not too far off from the future that Chris talks about being a reality. #patientoutcomes #digitalsurgery #futureofhealthcare #fiberoptics

🌟 MedTech 2024: A Year of Big Moves! 🌟 Who are the biggest spenders of 2024 in MedTech? This post features the first half of 2024, which saw major MedTech deals by household names including Boston Scientific, Johnson & Johnson and BD driving innovation and growth. A huge deal that stands out in particular was for a staggering $13.1bn!!💲 Surprisingly Stryker and their CEO Kevin Lobo is not named in the top 5 as they continue their aggressive play in H2. So far in 2024 Stryker have completed 6 deals focusing on #orthopaedics and #healthcareIT bringing their total to 54 acquisitions with an average acquisition amount of $743m according to Tracxn. I have listed the top 5 Deals by value in revenue, please click through to see who has been involved in the biggest deals so far in 2024 and compiled some further insight to the deals below. J&J, who boast the biggest deal so far of 2024, their CFO Joseph Wolk who said in a report that J&J can expect to see sales increase for H2 this year and so far we have seen their stock price go from $146ps to $168ps (19th Sep) it's the highest since August 2023 ($168ps) which demonstrated the positive impact following a $13.1bn acquisition. Edwards Lifesciences CFO, Scott Ullem who was significantly involved in the spin-out of the Critical Care division to BD said that the deal was a $4.2bn "Win Win" for both parties, as the business was performing well but Edwards are focusing their priorities on Structural Heart. Boston Scientific spent $4.96bn so far in 2024 on Axonics, Inc. and Silk Road Medical, Inc. significantly strengthening its cardiology focus on 2 big deals. well done to Mike Mahoney and team. You can read more in MedTechDive's article below: https://lnkd.in/eHcYqZQc #MedTech #HealthcareInnovation #AI #Robotics #MergersAndAcquisitions

Join us today at 4:00 PM in the Keynote Theater for the MedTech Innovator Finals! Five groundbreaking companies—BrainSpace, Flow Medical, Juniper Biomedical, NeuroBionics, and Samay—will present to a panel of industry leaders and compete for the $350K grand prize and the title of MedTech Innovator 2024, with the winner decided by your live vote! Don’t miss this exciting session as we celebrate the best in #medtech innovation and discover the next big breakthroughs. #MedTechCon #medtechinmotion

🌟 When the ecosystem comes together, amazing things happen! Proud to share the latest milestone from one of our #FutureofHealthcareFounderResidency companies: Coredio, a startup developing breakthrough cardiac monitoring technology, has submitted their FDA breakthrough device designation application. Their technology could transform how we monitor heart failure patients, providing critical cardiac measurements without invasive procedures. This achievement represents months of collaboration with The Roux Institute at Northeastern University regulatory expert and mentor Dave Shoemaker, whose 21 years of regulatory experience with the U.S. Army and FDA has proved invaluable. This is what meaningful ecosystem-building looks like - connecting innovative founders with experienced mentors to advance healthcare solutions that matter. Special shout-out to Jeff Chu for providing strategic guidance to Mehdi Mortazawy and Yashar Seyed Vahedein, Ph.D. as their EIR and helping them get to this point! You have created such a mentality of structure and support! Up next this team will begin work with Saeed Amal, from the Amal Precision Medicine Lab at The Roux to continue development of their novel technology! Grateful to be a part of this work and to work with such dedicated mentors, founders, and researchers! Read more about their journey here https://lnkd.in/eW2Cwzm9 #HealthcareInnovation #Maine #MedTech #Innovation #RouxInstitute #futureofhealthcare Allyson Goida Chris Wolfel Chris TorinaWarren Adams

Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical was the biggest medtech deal of 2024. Medtech dealmaking picked up in 2024 with ~40 deals signed/closed. Here's the link to Top 10 medtech deals of 2024 nicely captured by MedTech Dive Will 2025 be another busy year? There is a constant chatter about AI as medical device companies are keen on integrating AI into their products and services. Will medtech companies turn towards AI deals in 2025? It will be interesting to see. https://lnkd.in/dP9_YG3N

🔥 FIRE1 completed a $120m #financinground to advance its #heartfailure management system. The company also reached a major FDA milestone with breakthrough device designation. The funding — led by Polaris Partners and Elevage Medical Technologies — enables the completion of a pivotal clinical trial. New investors Sands Capital and Longitude Capital participated as well. Existing investors Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates (NEA), Novo Holdings, and Seventure Partners, all joined in. 👏 CEO Conor Hanley and team! 🔎 Learn more: https://lnkd.in/dYqhZ_p4 #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #AngelInvestment #GSCapitalConnect

🚨 Big News in Medical Tech 🚨 Route 92 Medical, a neurovascular interventional solutions company based in San Mateo, just raised $50M in Series F extension funding! 💰 Led by Novo Holdings, the round also included US Venture Partners, Norwest Venture Partners, InnovaHealth Partners, LP, and The Vertical Group. 🏦 In connection with the investment, Noel Jee, Partner, Growth Investments, Novo Holdings US, joins the Route 92 Board of Directors. 🎯 What’s Next? The funding will accelerate global commercialization of their neurovascular intervention portfolio and support regulatory approvals in new regions. 🌍 Why it Matters: With innovations like the FreeClimb, HiPoint Catheter Systems, and the Monopoint® Operating Platform—powered by the Tenzing® Delivery Catheter—Route 92 is simplifying stroke treatment by streamlining procedures, reducing time and cost, and improving outcomes. ⏱️💡 CEO Tony Chou emphasizes how this investment will help Route 92 continue collaborating with neurovascular clinicians to solve real-world challenges and deliver differentiated solutions for better patient care. 🏥 Noel Jee, Partner at Novo Holdings, joins the Board of Directors to further drive this mission forward. 📈 💼 Transforming neuro intervention, one innovation at a time! 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #MedicalTech #Neurovascular #Funding #Innovation #Healthcare #Route92 #PatientCare #FutureTechly